Revolutionizing CAD
Risk Screening for Longer, Healthier Lives
At HeartForce, we envision a world where coronary artery disease (CAD) can be detected early, quickly, accurately, and without unnecessary cost or complexity. Our mission is to enable preventive heart screening for all, empowering healthcare systems to save more lives through earlier intervention.
Our founding principles—accessibility, scientific integrity, and meaningful innovation—guide everything we do. We don’t think early detection should rely on symptoms alone or the ability to access complex diagnostics. With our revolutionary technology, we’re transforming how and when CAD is discovered.
Fast, non-invasive, radiation-free and evidence-based screening, suitable for symptomatic and high risk patients with multiple CAD-associated risk factors alike.
A smarter future for heart health
Fast test results in just 60 seconds, non-invasive, and radiation-free
Evidence-based and clinically proven
Intended for both symptomatic and high risk patients with multiple CAD-associated risk factors
Scalable across primary care, pharmacies, ambulances, occupational & institutional medicine settings, hospital’s emergency centers and cardiology departments
And we're just getting started
HeartForce is developing a full pipeline of user-friendly screening products for a wide range of cardiovascular diseases. Every new product that we create is intended to:
Detect disease before it strikes
Decrease global healthcare costs
Reduce cardiovascular morbidity/mortality
Enhance quality of life at scale
We believe that longer, healthier lives should be within reach for everyone, and we're here to make that possible.
Pioneering the Future of Heart Health, One Milestone at a Time
From our earliest breakthroughs in cardiac performance monitoring to the development of our clinically validated EMCR Score™, every step of our journey reflects our commitment to saving lives through smarter, earlier CAD risk screening. These milestones represent more than progress, they mark the foundation of a global transformation in preventive heart care.
- New management shifts the company's focus from resynchronization therapy for pacemakers to the early detection of coronary artery disease (CAD), the number one cause of death in the world¹.
- Development of a consumer-facing device enabling cardiac self-assessment through the integration of Cardiac Performance Metrics (CPM).
- Completion of proprietary algorithms focused on analyzing heart strength, rhythm, and timing.
- Strategic refinement of algorithms with a sole focus on coronary artery disease (CAD) detection, culminating in the development of the proprietary EMCR Score™.
- Completion of a multi-center clinical study in Uzbekistan involving over 2,000 patients, using CCTA and invasive coronary angiography (ICA) to validate and confirm the accuracy of our CAD screening technology.
- Demonstration of EMCR Score’s ability to detect high risk CAD cases.
- Successfully developed and finalized the CardioClin, targeted for healthcare professionals.
- Electrical safety and essential performance certification under IEC 60601-1.
- ISO 13485 / MDSAP quality system certification.
- Submission of cost-effectiveness research to the Canadian Device Assessment Agency (CDA-AMC, formerly CADTH).
- Securing provincial billing codes across OHIP (Ontario), MSP (British Columbia), and AHCIP (Alberta), with the submission of the cost-effectiveness paper serving as the basis.
- Preparation for submission of the Health Canada medical device license application, and CE-mark and Europe MDR approval.
- FDA 510K pre-submission request submitted.
- We have completed manufacturing of new CardioClin™ sensor molds, designed to support higher production volumes and flexibility, while meeting stringent material quality standards and enabling easy device cleaning.
- Upgrade of the user-experience and functionality of the CardioClin™ application.
In Progress
Future Innovation
CardioPro: Enabling Smarter Heart Health
At HeartForce, we are continuing to research the potential of our technology for other cardiac abnormalities that can be screened/diagnosed using our CardioClin™ device. We have already examined the potential of CardioClin for detection of arrhythmia and valvular disease. Our next innovation going forward, CardioPro, will put medical-grade cardiac screening and real-time heart performance monitoring in consumers’ hands, anytime, anywhere.
CardioPro™ is a next-generation, portable device that combines advanced signal analysis, AI-driven diagnostics, and intuitive design to provide personalized cardiovascular insights within 60 seconds.
Key characteristics are:
- Medical-grade heart screening in a consumer-friendly format
- Real-time SCG signal analysis through our patented cloud-based algorithm
- Seamless data sharing with the person’s healthcare provider for timely follow-up
- Multi-condition screening for CAD, atrial fibrillation, arrhythmias and PVCs
CardioPro is a bold step toward proactive, personalized cardiac care, allowing patients to take charge of their heart health and facilitating earlier, better-informed intervention.
Investor Relations
References
- Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. PubMed.
https://pubmed.ncbi.nlm.nih.gov/32119297/